These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19335066)

  • 21. Signaling pathways in hepatocellular carcinoma.
    Sia D; Villanueva A
    Oncology; 2011; 81 Suppl 1():18-23. PubMed ID: 22212931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
    Shen YC; Hsu C; Cheng AL
    J Gastroenterol; 2010 Aug; 45(8):794-807. PubMed ID: 20567987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of advanced hepatocellular carcinoma].
    Forner A; Rodríguez De Lope C; Reig M; Bruix J
    Gastroenterol Hepatol; 2010; 33(6):461-8. PubMed ID: 20227796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of systemic therapy of advanced hepatocellular carcinoma.
    Yau T; Chan P; Epstein R; Poon RT
    World J Gastroenterol; 2008 Nov; 14(42):6437-41. PubMed ID: 19030192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting tyrosine kinase receptors in hepatocellular carcinoma.
    Muntané J; De la Rosa AJ; Docobo F; García-Carbonero R; Padillo FJ
    Curr Cancer Drug Targets; 2013 Mar; 13(3):300-12. PubMed ID: 23016985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
    Wang Z; Hu J; Qiu SJ; Huang XW; Dai Z; Tan CJ; Zhou J; Fan J
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1039-45. PubMed ID: 21671804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatocellular carcinoma].
    Yamashita T; Arai K; Kaneko S
    Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular targeted therapies in hepatocellular carcinoma.
    Llovet JM; Bruix J
    Hepatology; 2008 Oct; 48(4):1312-27. PubMed ID: 18821591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib for HCC: a pragmatic perspective.
    Razumilava N; Gores GJ
    Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
    [No Abstract]   [Full Text] [Related]  

  • 33. Sorafenib.
    Rini BI
    Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New pharmacological developments in the treatment of hepatocellular cancer.
    Gusani NJ; Jiang Y; Kimchi ET; Staveley-O'Carroll KF; Cheng H; Ajani JA
    Drugs; 2009; 69(18):2533-40. PubMed ID: 19943706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
    Pazo-Cid RA; Lanzuela M; Esquerdo G; Pérez-Gracia JL; Antón A; Amigo G; Trufero JM; García-Otín AL; Martín-Duque P
    Clin Transl Oncol; 2012 Aug; 14(8):564-74. PubMed ID: 22855137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The hepatocellular carcinoma: alternative therapeutical strategies].
    Spangenberg HC; Thimme R; Mohr L; Blum HE
    Zentralbl Chir; 2007 Aug; 132(4):322-7. PubMed ID: 17724635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
    Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
    Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.